|
C20ORF194 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.25089999364536E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.18149999678496E-08 |
| Normal-vs-Stage2 |
9.544700E-03 |
| Normal-vs-Stage3 |
9.45360001392004E-09 |
| Normal-vs-Stage4 |
2.51070000012454E-07 |
| Stage1-vs-Stage2 |
1.009000E-01 |
| Stage1-vs-Stage3 |
1.218620E-01 |
| Stage1-vs-Stage4 |
1.184000E-01 |
| Stage2-vs-Stage3 |
1.573630E-02 |
| Stage2-vs-Stage4 |
1.965930E-02 |
| Stage3-vs-Stage4 |
7.276200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.73510008980327E-10 |
| Normal-vs-AfricanAmerican |
3.310100E-02 |
| Normal-vs-Asian |
2.612800E-04 |
| Caucasian-vs-AfricanAmerican |
6.884500E-02 |
| Caucasian-vs-Asian |
2.817800E-01 |
| AfricanAmerican-vs-Asian |
3.780200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.81629996890365E-09 |
| Normal-vs-Female |
4.16780000511707E-08 |
| Male-vs-Female |
3.506600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.61620000049822E-07 |
| Normal-vs-Age(41-60Yrs) |
1.02470000040711E-07 |
| Normal-vs-Age(61-80Yrs) |
9.26749999963228E-07 |
| Normal-vs-Age(81-100Yrs) |
6.802700E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.223200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.257600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.293400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.499400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.132000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.866800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.840020E-03 |
| Classical-VS-Follicular |
5.493800E-02 |
| Classical-VS-Other |
3.169000E-01 |
| Classical-VS-Normal |
2.38639996652523E-09 |
| Tall-VS-Follicular |
1.568300E-04 |
| Tall-VS-Other |
7.375400E-01 |
| Tall-VS-Normal |
1.16629994550976E-09 |
| Follicular-VS-Other |
2.078100E-02 |
| Follicular-VS-Normal |
8.855300E-03 |
| Other-VS-Normal |
1.445380E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.19420000005621E-07 |
| Normal-vs-N1 |
1.47849999998506E-06 |
| N0-vs-N1 |
2.113000E-01 |
|
|
